Does Tufts Health Plan Cover Prolia?

What Is Prolia and Why Does Coverage Get Complicated?

Prolia is a RANK ligand inhibitor that reduces osteoclast activity and slows bone resorption. The FDA approved it in June 2010 for postmenopausal women with osteoporosis at high fracture risk, later expanding the label to include bone loss from androgen-deprivation therapy and aromatase-inhibitor therapy [1]. Because it is a biologic drug administered by injection every six months in a physician's office, it is almost always billed through the medical benefit rather than the pharmacy benefit, which changes the coverage rules considerably.

When a drug is billed under the medical benefit, the insurer's utilization-management criteria, not the pharmacy formulary tier, govern whether the claim pays. Tufts Health Plan, which operates both commercial plans and Medicare Advantage products in Massachusetts and New England, applies medical-benefit drug policies that mirror the clinical criteria published by major specialty societies including the American Society for Bone and Mineral Research and the Endocrine Society [2].

The FREEDOM trial (N=7,868) demonstrated that denosumab reduced new vertebral fractures by 68% over 36 months compared with placebo (7.2% placebo vs. 2.3% denosumab, P<0.001) and reduced hip fractures by 40% (P<0.001) [3]. That trial evidence is what insurers use to justify covering the drug at all. It is also what your prescribing physician should cite when submitting a prior-authorization request.

How Tufts Health Plan Structures Prolia Coverage

Tufts Health Plan operates several distinct product lines. Coverage rules differ meaningfully between them.

Commercial employer plans (Tufts Health Direct, Tufts Health Together, etc.): These plans typically carry a medical-drug benefit that includes injectables administered in a physician's office. Prolia falls into a specialty tier equivalent. Most commercial contracts require prior authorization, and many include a step-therapy requirement mandating a trial of an oral bisphosphonate (alendronate, risedronate, or ibandronate) before denosumab is approved, unless a documented contraindication or intolerance exists.

Tufts Medicare Advantage (Senior Care Options, HMO plans): Medicare Part B generally covers drugs administered in a clinical setting at 80% of the Medicare-approved amount after the Part B deductible, and Tufts Medicare Advantage plans follow that structure with possible cost-sharing modifications. Prior authorization is still required on many MA plans. The 2023 CMS coverage determination confirms denosumab is a Part B-covered drug when medically necessary and administered by a qualified provider [4].

Tufts Medicaid (managed through MassHealth): Coverage through MassHealth-contracted Tufts plans is subject to MassHealth's Preferred Drug List. As of current PDL guidance, denosumab requires prior authorization with documented failure of or contraindication to an oral bisphosphonate.

Prior Authorization Criteria: What Tufts Typically Requires

Prior authorization for Prolia on Tufts plans generally requires the following documentation, based on published Tufts medical-policy language and standard commercial insurer criteria for denosumab:

1. Confirmed diagnosis of osteoporosis or high fracture-risk osteopenia. The prescribing provider must supply a DXA scan result showing a T-score <-2.5 at the lumbar spine, femoral neck, or total hip, or a T-score between -1.0 and -2.5 accompanied by a FRAX 10-year major fracture probability at or above the National Osteoporosis Foundation threshold (10% for major osteoporotic fracture or 3% for hip fracture) [5].

2. Step therapy documentation. Most Tufts commercial plans require evidence of at least three to six months of trial with an oral bisphosphonate (most commonly alendronate 70 mg weekly or risedronate 35 mg weekly) unless the patient documents gastrointestinal intolerance, esophageal disease, inability to remain upright for 30 minutes, or chronic kidney disease with an eGFR <35 mL/min/1.73 m2. Oral bisphosphonates are contraindicated when eGFR falls below that threshold per FDA labeling [6].

3. Diagnosis-specific label alignment. The indication must match the FDA-approved label: postmenopausal osteoporosis, glucocorticoid-induced osteoporosis, male osteoporosis, or bone loss secondary to ADT or AI therapy [1].

4. Prescriber type. Many Tufts PA policies specify that the ordering provider be a physician, nurse practitioner, or physician assistant with a relevant specialty background (endocrinology, rheumatology, obstetrics/gynecology, primary care with documented osteoporosis management) or that the patient be under the care of such a provider.

The Endocrine Society's 2019 clinical practice guideline states: "Denosumab is an option for patients with osteoporosis who cannot use oral bisphosphonates or who require more potent anti-resorptive therapy" [2]. That language is exactly the kind of guideline quotation a PA letter should include.

Step Therapy: The Bisphosphonate Hurdle

Step therapy for osteoporosis drugs is common across commercial insurers. The reasoning is cost containment: generic alendronate costs roughly $10-$25 per month while Prolia's list price is approximately $1,380 per dose (two doses per year). For patients who tolerate bisphosphonates and have no contraindications, insurers view the oral drugs as clinically appropriate first-line treatment based on AACE/ACE guidance [7].

However, step therapy does not apply universally. The following patients may qualify for a step-therapy waiver on most Tufts plans:

• Documented GI intolerance or history of esophageal stricture, Barrett's esophagus, or active esophagitis.
• eGFR <35 mL/min/1.73 m2 (bisphosphonate contraindication per labeling [6]).
• History of atypical femoral fracture or osteonecrosis of the jaw attributable to prior bisphosphonate use.
• Documented prior fracture while on adequate bisphosphonate therapy (treatment failure).
• Malabsorption syndromes (Crohn's disease, celiac disease, post-bariatric surgery) that reduce oral drug absorption.

Massachusetts enacted step-therapy reform provisions under Chapter 260 of the Acts of 2018, which require health plans to grant exceptions within 72 hours for urgent cases and 14 days for standard requests when a clinician certifies that step therapy is clinically contraindicated [8]. Your prescribing physician can invoke this statute when submitting the PA request.

The Prior Authorization Submission Process, Step by Step

Getting Prolia approved through Tufts requires a coordinated effort between the patient, the prescribing clinician, and occasionally the infusion or physician-office billing staff. Below is the sequence most likely to succeed on the first submission.

Step 1: Obtain a current DXA scan. The scan must be performed at a facility with ISCD-certified technology and read by a radiologist or DXA technologist using standardized T-score reporting. DXA results more than 24 months old may be rejected.

Step 2: Calculate FRAX. Use the WHO FRAX calculator (available at shef.ac.uk/FRAX) to generate a 10-year fracture probability. Include femoral neck BMD in the calculation for the most accurate risk estimate [5].

Step 3: Document bisphosphonate history or contraindication. Pull pharmacy records, office notes, or GI consultation reports. A letter of medical necessity from a gastroenterologist stating why oral bisphosphonates cannot be used carries significant weight.

Step 4: Complete the Tufts PA form. Tufts Health Plan's provider portal (available to in-network providers) hosts the medical-drug prior-authorization forms. For Medicare Advantage members, CMS requires that PA decisions for Part B drugs be made within 14 days (standard) or 72 hours (expedited) [4].

Step 5: Include the letter of medical necessity. The letter should cite the FREEDOM trial data [3], the Endocrine Society guideline language [2], and the specific patient-level data (T-score, FRAX score, prior fracture history, comorbidities).

Step 6: Track the decision timeline. Under Massachusetts law, commercial insurers must render PA decisions within two business days for urgent requests and five business days for standard requests [8].

What to Do If Tufts Denies Coverage for Prolia

A denial is not the end. Denial rates for specialty biologics on first submission run around 30-40% across commercial insurers, but appeal overturn rates can exceed 50% when the clinical record is complete.

Internal appeal. File within 30 days of the denial notice. Request a peer-to-peer review, where your physician speaks directly with the Tufts medical director who issued the denial. This single step overturns a meaningful share of specialty-drug denials. The physician should reference the FREEDOM trial's 68% vertebral fracture-reduction data [3] and the patient's specific fracture risk.

External review. If the internal appeal fails, Massachusetts members have the right to an independent external review through the Office of Patient Protection. The external reviewer is not employed by Tufts and must render a decision within 45 days (standard) or 72 hours (expedited for urgent medical situations) [8].

Exception request under step-therapy law. If the denial is based on step-therapy non-compliance, invoke the Chapter 260 exception process and provide written clinical justification. The insurer must respond within the statutory timeframes.

File a complaint with the Massachusetts Division of Insurance. If Tufts violates the response timelines or fails to provide a written explanation of denial, the Division of Insurance (mass.gov/doi) accepts complaints and can compel compliance.

Cost-Sharing When Prolia Is Approved

Approval does not mean zero out-of-pocket cost. Under the medical benefit, Prolia is typically subject to the plan's specialist office co-pay plus any applicable drug-administration charge, or it may be subject to coinsurance after the deductible.

For commercial plans, the member may owe a co-pay of $40-$100 per visit plus a percentage of the drug cost (10-30% coinsurance depending on the plan tier). For a $1,380 list-price injection, 20% coinsurance equals $276 per dose before any discount programs.

For Medicare Advantage members, Part B cost-sharing rules apply. After the 2025 Part B deductible of $257, Medicare pays 80% of the approved amount. The MA plan's supplemental coverage determines the remaining 20%.

Amgen's FIRST STEP patient-assistance program can reduce co-pays to $0 for commercially insured patients who meet eligibility criteria (the program excludes federally funded insurance such as Medicare and Medicaid) [9]. The program is accessible at amgensupportive.com/prolia.

Alternatives When Prolia Is Denied or Unaffordable

If Prolia coverage cannot be secured despite a thorough appeal, other FDA-approved osteoporosis agents may be accessible under a different benefit structure.

Alendronate (generic oral bisphosphonate): Covered as a Tier 1 generic on virtually all pharmacy plans. At 70 mg weekly, it reduces vertebral fracture risk by approximately 47% and hip fracture risk by 51% over three years in the FIT trial (N=2,027) [10].

Zoledronic acid (Reclast IV, once yearly): Infused annually. The HORIZON Key Fracture Trial (N=7,765) showed a 70% reduction in vertebral fractures over 36 months [11]. Covered under the medical benefit similarly to Prolia; prior authorization is also typically required but the cost point is lower.

Romosozumab (Evenity): A sclerostin inhibitor approved for postmenopausal women at high fracture risk. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced major osteoporotic fracture risk by 27% versus alendronate alone [12]. List price is higher than Prolia; coverage availability is similar.

Teriparatide (Forteo) or abaloparatide (Tymlos): Anabolic agents for severe osteoporosis with prior fracture. These carry their own PA requirements and cost considerations.

The 2022 American Association of Clinical Endocrinology clinical practice guideline recommends anabolic-first therapy for patients with very high fracture risk (T-score <-3.0 with prior fracture), which could support a PA for Prolia or romosozumab over bisphosphonates in the right clinical context [7].

Special Situations That Affect Coverage

Prolia for male osteoporosis. The FDA approved denosumab for osteoporosis in men at high fracture risk in September 2012. Tufts plans that follow FDA-label indications will cover this use with appropriate PA documentation, including DXA results and exclusion of secondary causes of bone loss.

Glucocorticoid-induced osteoporosis (GIOP). Prolia received FDA approval for GIOP in January 2018 for patients taking the equivalent of at least 7.5 mg/day prednisone for six or more months. Coverage may require documentation of the steroid dose, duration, and inability to use oral bisphosphonates [1].

Bone loss from ADT or AI therapy. Men with prostate cancer on androgen-deprivation therapy and women with breast cancer on aromatase-inhibitor therapy are FDA-labeled Prolia indications. Tufts plans should cover these indications with oncology or urology documentation. The DXA T-score threshold for initiation in this population may differ from general osteoporosis thresholds; American Society of Clinical Oncology guidance recommends initiating bone-protective therapy when T-score <-2.0 in this group [13].

Transitioning off Prolia. One clinically significant issue Tufts PA policies do not always address explicitly is the rebound effect after Prolia discontinuation. Stopping denosumab without transitioning to a bisphosphonate causes rapid BMD loss and a measurable increase in vertebral fracture risk within 12 to 24 months, as documented in the FREEDOM extension follow-up data [3]. Your physician should document a transition plan in the PA request to support ongoing coverage or a bridge strategy.

Physician Tips for Maximizing First-Pass Approval

Physicians and advanced practice providers submitting Prolia PAs to Tufts can meaningfully improve first-pass approval rates with these documentation practices.

Include the actual DXA numbers, not just a narrative description. Write "T-score of -2.8 at the femoral neck on DXA performed January 10, 2025 at [facility]" rather than "patient has osteoporosis."

Cite the FREEDOM trial by name and number [3]. PA reviewers are trained to look for clinical evidence, and a letter that references a specific trial demonstrates that the prescribing clinician has engaged with the literature.

State the step-therapy history with dates. "Patient trialed alendronate 70 mg weekly from March 2024 to September 2024. Discontinued due to severe GERD and reflux esophagitis documented by EGD performed October 2024 (Dr. [name], gastroenterology)." That sentence closes the step-therapy gate.

Request a peer-to-peer review proactively. Some PA systems allow the submitting provider to request peer-to-peer at the time of submission rather than waiting for a denial. Tufts provider relations can confirm whether this is available on your plan type.

The American Society for Bone and Mineral Research states in its 2022 task force position paper: "Sequential and combination therapy strategies should be individualized, and discontinuation of anti-resorptive therapy without a planned transition represents an avoidable clinical risk" [14]. That framing supports PA requests for both initial therapy and continuation of Prolia after the first year.